Literature DB >> 27354255

Ventricular volume and myocardial viability, evaluated using cardiac magnetic resonance imaging, affect long-term results after surgical ventricular reconstruction.

Sachiko Yamazaki1, Kiyoshi Doi2, Satoshi Numata2, Keiichi Itatani2, Hidetake Kawajiri2, Kazuki Morimoto2, Kaichiro Manabe2, Koki Ikemoto2, Hitoshi Yaku2.   

Abstract

OBJECTIVES: We aimed to investigate the outcomes of surgical ventricular reconstruction (SVR) for ischaemic cardiomyopathy and to identify ideal candidates for this procedure using cardiac magnetic resonance imaging (MRI) studies.
METHODS: We retrospectively examined 50 patients who underwent SVR and were preoperatively evaluated using cardiac MRI from 2004 to 2014. Cine MRI and gadolinium-enhanced MRI were performed to evaluate left ventricular (LV) volume and scarring. The midterm (median, 2.5 years) risk factors of cardiac death or major adverse cardiac events (MACEs) were analysed. Patients were divided into three groups-those with preoperative indexed LV end-systolic volume (LVESVI) of ≤100 ml/m2 (Group 1), those with LVESVI of >100 and ≤130 ml/m2 (Group 2) and those with LVESVI of >130 ml/m2 (Group 3)-and examined.
RESULTS: In total, 17 patients exhibited MACEs at follow-up. Kaplan-Meier analysis showed that the 5-year rate of freedom from MACEs was 66%. The Cox hazard model indicated that preoperative LVESVI was the only significant predictor for MACEs (P = 0.006; hazard ratio, 1.02; 95% confidence interval, 1.01-1.04). Moreover, a significant reduction in LVESVI and an increase in LV ejection fraction (LVEF) were observed early after SVR (preoperative versus postoperative: LVESVI, 110 ± 44 vs 68 ± 28 ml/m2, P < 0.001; LVEF, 24.3 ± 10.3 vs 32.0 ± 10.4%, P < 0.001) and at follow-up (LVESVI, 61 ± 28 ml/m2, P < 0.001; LVEF, 36.5 ± 11.5%, P < 0.001). Although no difference was observed between the groups at follow-up, LVEF and LVESVI primarily improved in Group 2. LVEF improvement was significantly greater in Group 2 than in Group 1 (%increase in LVEF: Group 1, 6%; Group 2, 18%; P = 0.008). In patients with a preoperative LVESVI of >130 ml/m2, the number of non-viable segments was a significant risk factor for MACEs.
CONCLUSIONS: Patients with preoperative LVESVI ranging from 100 to 130 ml/m2 had fairly better outcomes, and the percentage improvement in LVEF and the percentage reduction in LVESVI were more pronounced in these patients. Hence, accurate preoperative assessments of LV volume and viability testing using cardiac MRI studies are essential for better stratification of the SVR procedure.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Cardiovascular magnetic resonance imaging; Left ventricular end-systolic volume index; Surgical ventricular reconstruction; Viability

Mesh:

Year:  2016        PMID: 27354255     DOI: 10.1093/ejcts/ezw213

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Significance of preoperative right ventricular function on mid-term outcomes after surgical ventricular restoration for ischemic cardiomyopathy.

Authors:  Koji Furukawa; Mitsuhiro Yano; Masanori Nishimura; Eisaku Nakamura; Nozomi Watanabe; Shun Nishino; Kunihide Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-04-09

2.  A single center's experience with total arterial revascularization and spiral aneurysmorrhaphy for ischemic cardiac disease.

Authors:  Ilias P Doulamis; Despina N Perrea; George Mastrokostopoulos; Konstantina Drakopoulou; Konstantinos Voutetakis; Aspasia Tzani; Ioannis A Chloroyiannis
Journal:  Heart Vessels       Date:  2018-12-06       Impact factor: 2.037

3.  Effect of preoperative left ventricular diastolic dysfunction on mid-term outcomes after surgical ventricular restoration for ischemic cardiomyopathy.

Authors:  Koji Furukawa; Mitsuhiro Yano; Eisaku Nakamura; Masakazu Matsuyama; Masanori Nishimura; Katsuya Kawagoe; Kunihide Nakamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-04-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.